


**Product Name** : CA-4948  
**Cat. No.** : PC-50002  
**CAS No.** : 1801344-14-8  
**Molecular Formula** : C<sub>24</sub>H<sub>25</sub>N<sub>7</sub>O<sub>5</sub>  
**Molecular Weight** : 491.508  
**Target** : IRAK  
**Solubility** : 10 mM in DMSO



1. Robert Booher, et al. 1534 Combination of IRAK4 Inhibitor CA-4948 with BCL2 Inhibitor Venetoclax Induces Tumor Regression in an ABC-DLBCL Xenograft Model. Bldg A, Lvl 1, Hall A2

## Biological Activity

Emavusertib (CA-4948) is a potent, selective and orally active **IRAK4** inhibitor with IC<sub>50</sub> of 31.7 nM.

Emavusertib (CA-4948) exhibits significant activity against a handful of other kinases such as CLK1, CLK2, CLK4, FLT3, DYRK1A, DYRK1B, TrkA, TrkB, Haspin, and NEK11 in a panel of a broad kinome panel (329 kinases).

Emavusertib (CA-4948) showed good modulation of IL6 in human whole blood assay and pIRAK1 modulation (IC<sub>50</sub> of 270 nM) in MV4-11 cell-line.

Emavusertib (CA-4948) demonstrated moderate potency in OCI-Ly10 (IC<sub>50</sub> = 1.5 μM) harboring MYD88 mutation in cellular growth inhibition assay in a short panel of lymphoma cell lines.

Emavusertib (CA-4948) showed >90% tumor growth inhibition in relevant tumor models with excellent correlation with in vivo PD modulation.

## References

- (Georgia World Congress Center).
- Gummadi VR, et al. *ACS Med Chem Lett.* 2020 Oct 14;11(12):2374-2381.
- Zhang S, et al. *Front Immunol.* 2021 Mar 9;12:637659.

